Perelman School of Medicine at the University of Pennsylvania

Penn Institute for Immunology

David T. Teachey

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Colket Translational Research Building, Room 3008
3501 Civic Center Boulevard
Philadelphia, PA 19104
Office: 2674265802
Fax: 2155903770
BS (Magna cum laude with Honors in Biology)
Virginia Commonwealth University, 1993.
MD (Medicine)
Eastern Virginia Medical School, 1999.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My basic science research focuses on two areas. My first area of interest centers on signal transduction pathways and inhibitors of those pathways in acute lymphoblastic leukemia (ALL). My lab targets a number of signaling pathways with novel therapeutics and uses xenograft models to study the efficacy of agents and mechanism of action of those agents directly on leukemia cells obtained from children. This work has led to a number of nationwide Children's Oncology Group-initiated clinical trials testing novel agents in patients with ALL. Recently, I have started to focus on investigating novel agents in very high risk subsets of ALL, including T-ALL.

The other major area of basic research in my lab centers on investigating novel therapeutics and signaling pathways in autoimmune diseases. I focus on a rare pediatric disorder called autoimmune lymphoproliferative syndrome (ALPS). Using preclinical models, I am targeting both mTOR and Notch signaling as treatment approaches for patients with ALPS and other autoimmune diseases. I am also interested in understanding lymphocyte biology in ALPS and other autoimmune diseases.

My clinical research is focused on investigating novel therapies for children with ALL and ALPS. I am on the study committee for a number of national childhood ALL trials, performing correlative biology for many of these studies. I am also the principal investigator for a local (CHOP) clinical trial that is using the mTOR inhibitor rapamycin in children with multiple medical conditions, including ALPS, chronic ITP, and lupus.

Description of Clinical Expertise

My clinical interests include pediatric leukemia and autoimmune disease with emphasis on acute lymphoblastic leukemia, lymphoproliferative disorders, and hematopoietic stem cell transplant.

Selected Publications

Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, McMann JM, Sullivan KE, Travis SF, Grupp SA: Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105(6): 2443-8, March 2005.

Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, Hulitt J, Manno CS, Maris JM, Rhodin N, Sullivan KE, Brown VI, Grupp SA: Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 108(6): 1965-71, September 2006.

Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA: Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 145(1): 101-6 April 2009.

Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang Y, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay P, Grupp SA.: Targeting notch signaling in autoimmune and lymphoproliferative disease. Blood 111(2): 705-14, January 2008 Notes: Article received featured commentary.

Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107(3): 1149-55, February 2006.

Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J, Reid GS, Seif AE, Norris R, Chang YJ, Carroll M, Grupp SA: mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112(5): 2020-3, September 2008.

Teachey DT, Grupp SA, and Brown VI: Mammalian target of rapamycin inhibitors and their potential role for therapy in leukemia and other haematologic malignancies. Br J Haematol 145(5): 569-80, June 2009.

Teachey DT: Neonatal MRI and neurodevelopmental outcomes. N Engl J Med 355(22): 2374, November 2006.

Seif AE, Manno CS, Sheen C, Grupp SA, and Teachey DT: Identifying autoimmune lymphoproliferative syndrome (ALPS) in children with Evans syndrome: a multi-institutional study. Blood 115(11): 2142-5, March 2010

Teachey DT, Seif AE, Grupp SA: Advances in the managment and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol 148(2): 205-16, January 2010.

back to top
Last updated: 04/26/2018
The Trustees of the University of Pennsylvania